KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Thermo Fisher Scientific (TMO) over the last 17 years, with Q3 2025 value amounting to $2.0 billion.

  • Thermo Fisher Scientific's Cash & Equivalents fell 5733.05% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 5733.05%. This contributed to the annual value of $4.0 billion for FY2024, which is 5036.52% down from last year.
  • Latest data reveals that Thermo Fisher Scientific reported Cash & Equivalents of $2.0 billion as of Q3 2025, which was down 5733.05% from $4.6 billion recorded in Q2 2025.
  • Thermo Fisher Scientific's 5-year Cash & Equivalents high stood at $12.0 billion for Q4 2021, and its period low was $1.9 billion during Q3 2022.
  • Its 5-year average for Cash & Equivalents is $5.2 billion, with a median of $4.6 billion in 2025.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 7572.96% in 2022, then soared by 12575.81% in 2024.
  • Thermo Fisher Scientific's Cash & Equivalents (Quarter) stood at $4.5 billion in 2021, then surged by 90.4% to $8.5 billion in 2022, then decreased by 5.24% to $8.1 billion in 2023, then crashed by 50.37% to $4.0 billion in 2024, then plummeted by 50.56% to $2.0 billion in 2025.
  • Its Cash & Equivalents was $2.0 billion in Q3 2025, compared to $4.6 billion in Q2 2025 and $4.1 billion in Q1 2025.